论文部分内容阅读
目的:寻找减少早期糖尿病肾病患者的尿蛋白排出方法及更好地改善肾功能。方法:选择在理想的降血糖、降血压基础上的早期2型糖尿病肾病患者186例,随机分为3组,第1组:口服盐酸贝那普利;第2组:口服胰激肽原酶肠溶片;第3组:胰激肽原酶肠溶片联合贝那普利口服。结果:联合用药组治疗效果显著。结论:胰激肽原酶肠溶片联合盐酸贝那普利,对早期糖尿病肾病在减少尿蛋白排泄率上优于单用盐酸贝那普利或胰激肽原酶肠溶片,同时也延缓了糖尿病肾病病情。
OBJECTIVE: To find ways to reduce urinary protein excretion in patients with early diabetic nephropathy and to better improve renal function. Methods: One hundred and sixty-six patients with early type 2 diabetic nephropathy on the basis of ideal hypoglycemic and hypotensive effects were randomly divided into three groups: Group 1: oral benazepril hydrochloride; Group 2: oral kallikrein Enteric-coated tablets; Group 3: pancreatic kallikrein enteric-coated tablets combined with benazepril orally. Results: The combined treatment group had a significant therapeutic effect. CONCLUSIONS: The combination of pancreatic kallikrein enteric-coated tablets and benazepril hydrochloride is superior to the single-use benazepril hydrochloride or kallikrein enteric-coated tablets in reducing the urinary protein excretion rate of early diabetic nephropathy, Diabetic nephropathy condition.